152 related articles for article (PubMed ID: 30216494)
1. Serum fatty acid-binding protein 4 level is inversely correlated with serum thymus and activation-regulated chemokine level in psoriatic patients achieving clear skin by biologics.
Honma M; Shibuya T; Iinuma S; Ishida-Yamamoto A
J Dermatol; 2019 Apr; 46(4):e116-e117. PubMed ID: 30216494
[No Abstract] [Full Text] [Related]
2. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
3. Leucine-rich α-2 glycoprotein is an innovative biomarker for psoriasis.
Nakajima H; Serada S; Fujimoto M; Naka T; Sano S
J Dermatol Sci; 2017 May; 86(2):170-174. PubMed ID: 28179066
[No Abstract] [Full Text] [Related]
4. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.
Baran A; Kiluk P; Maciaszek M; Świderska M; Flisiak I
Arch Dermatol Res; 2019 Jul; 311(5):389-397. PubMed ID: 30993401
[TBL] [Abstract][Full Text] [Related]
5. Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.
Sano S
J Dermatol; 2017 Oct; 44(10):e234-e235. PubMed ID: 28623843
[No Abstract] [Full Text] [Related]
6. Persistent pruritus in psoriatic patients during administration of biologics.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Ishida-Yamamoto A
J Dermatol; 2018 Aug; 45(8):e223. PubMed ID: 29512183
[No Abstract] [Full Text] [Related]
7. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
van de Kerkhof PC; Mrowietz U; Segaert S; Kragballe K
Br J Dermatol; 2007 Apr; 156(4):771-2. PubMed ID: 17263798
[No Abstract] [Full Text] [Related]
9. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
[No Abstract] [Full Text] [Related]
10. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
Muramatsu S; Kubo R; Nishida E; Morita A
Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
[TBL] [Abstract][Full Text] [Related]
11. Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine.
Hernández-Breijo B; Jurado T; Rodríguez-Martín E; Martínez-Feito A; Plasencia-Rodríguez C; Balsa A; Alonso-Pacheco ML; Villar LM; Herranz-Pinto P; Pascual-Salcedo D
Br J Dermatol; 2018 Sep; 179(3):765-766. PubMed ID: 29526036
[No Abstract] [Full Text] [Related]
12. Serum thymus and activation-regulated chemokine (TARC/CCL17) levels reflect the disease activity in a patient with bullous pemphigoid.
Nin-Asai R; Muro Y; Sekiya A; Sugiura K; Akiyama M
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):327-8. PubMed ID: 25201568
[No Abstract] [Full Text] [Related]
13. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
Wright NA; Piggott CD; Eichenfield LF
Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
15. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
16. The role of biologics in the treatment of moderate-to-severe plaque psoriasis.
Puig L
G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100
[TBL] [Abstract][Full Text] [Related]
17. Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris.
Takahashi T; Asano Y; Shibata S; Tada Y; Sato S
J Dermatol; 2017 Feb; 44(2):205-206. PubMed ID: 28497874
[No Abstract] [Full Text] [Related]
18. Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels.
Miyagaki T; Sugaya M; Suga H; Morimura S; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):19-24. PubMed ID: 22077186
[TBL] [Abstract][Full Text] [Related]
19. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
[No Abstract] [Full Text] [Related]
20. Herpes Zoster Rates in a Large Cohort of Patients With Systemically Treated Psoriasis.
Levandoski KA; Quesenberry CP; Tsai AL; Asgari MM
JAMA Dermatol; 2018 Feb; 154(2):218-219. PubMed ID: 29261840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
